Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the phase 2b RELIEVE UCCD study of Teva's anti-TL1A antibody, duvakitug, in ulcerative colitis and Crohn’s disease

Ticker(s): TEVA, SNY

Who's the expert?

Institution: Northwestern University

Professor of Medicine and Medical Director of Digestive Health Center at Northwestern University
Treats more than 1000 patient per year for ulcerative colitis or Crohn’s diseas
Internationally recognized as an expert on IBD and has been an advisor on the development on multiple IBD drugs

Interview Goal

On this call we will be discussing the potential of Sanofi and Teva Pharmaceuticals' anti-TL1A antibody (TEV-48574 aka duvakitug) in development for ulcerative colitis and Crohn’s disease and the recent results from the phase 2b RELIEVE UCCD study.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.